0.62
-1.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beyondspring
From its filings with the US Securities and Exchange Commission
Beyondspring is based in Florham Park, New Jersey. Its shares trade on Nasdaq under the ticker BYSI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $1.0m. At that date it held total assets of $25.9m and shareholders' equity of −$32.2m.
We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Our first-in-class lead asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate “acquired resistance” from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. Plinabulin has been administered to over 700 cancer patients with generally good tolerability and is being developed as a potential “pipeline in a drug” in various cancer indications as a direct anti-cancer agent with safety benefit of reducing chemotherapy-induced neutropenia (CIN). After a successful phase 3 study (DUBLIN-3) in NSCLC, Plinabulin regimen is in a confirmatory global phase 3 study in second- and third-line NSCLC with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors, a severe unmet medical need. We are also developing three small molecule immune agents, which are currently in pre-clinical stages. In addition, we founded and continue to own an equity stake in SEED Therapeutics Inc., or SEED. See “—SEED’s relationship with BeyondSpring” for additional information. SEED is utilizing a proprietary Targeted Protein Degradation (TPD) drug discovery platform, or “molecular glue” technology, to develop innovative therapeutic agents from internal research and development efforts and with our collaborators on currently undruggable protein targets.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Mar 2017
- Employees
- 61
- Website
- beyondspringpharma.com/en ↗
- Head office
- 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NJ, 07932
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Lan HuangChairperson of the Board, Chief Executive Officer, Co-Founder, since 2014$793,432
- Dr. June LuChief Scientific Officer$497,972
- Mr. Sihai XuDirector$47,400
- Mr. Brendan DelaneyIndependent Director$55,400
- Mr. Patrick FabbioIndependent Director$63,400
- Mr. Matthew KirkbyIndependent Director$71,400
- Dr. Jiangwen MajetiIndependent Director$61,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 53
- Social
- 38
- Governance
- 81
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beyondspring Inc has several strengths that contribute to its success. Firstly, the company possesses a strong pipeline of innovative drugs, which provide opportunities for growth and expansion. Additionally, the company has a highly skilled and experienced management team that possesses deep expertise in the biopharmaceutical industry. This enables Beyondspring Inc to effectively navigate complex regulatory processes and drive strategic decision-making.
Weaknesses
- Despite its strengths, Beyondspring Inc also faces certain weaknesses that could hinder its growth. One major weakness is the company's heavy reliance on a limited number of drug candidates in its pipeline. This concentration of resources and risks exposes the company to potential setbacks if any of these candidates fail to receive approval or encounters unforeseen challenges. Moreover, the company's geographical presence is currently limited, which may restrict its market reach and impact its competitive position.
Opportunities
- Beyondspring Inc has various opportunities in the biopharmaceutical space. The increasing global demand for innovative cancer treatments presents a significant opportunity for the company to capitalize on its pipeline of novel drugs. Furthermore, potential partnerships and collaboration with other industry players can help expand the company's market access and accelerate drug development. Moreover, advancements in technology and personalized medicine offer opportunities for Beyondspring Inc to develop tailored treatments, enhancing patient outcomes.
Threats
- Alongside opportunities, Beyondspring Inc faces threats that could impact its performance. One significant threat is intense competition from both established pharmaceutical companies and emerging biotech firms. This competition can challenge the company's ability to secure market share and capture a significant patient population. Additionally, uncertainties surrounding regulatory policies and approvals pose a threat, as changes in regulations can impact drug development timelines and overall market conditions. Moreover, potential adverse events or safety concerns associated with the company's drugs could lead to reputational damage and loss of investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.